Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANP009
MIFTS: 44

Anaplastic Oligodendroglioma

Categories: Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anaplastic Oligodendroglioma

About this section

MalaCards integrated aliases for Anaplastic Oligodendroglioma:

Name: Anaplastic Oligodendroglioma 53 59 55 17 72
Oligodendroglioma, Anaplastic 6

Characteristics:

Orphanet epidemiological data:

59
anaplastic oligodendroglioma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 73 C0334590
Orphanet 59 ORPHA251630
UMLS 72 C0334590
Sources

Summaries for Anaplastic Oligodendroglioma

About this section
MalaCards based summary : Anaplastic Oligodendroglioma, also known as oligodendroglioma, anaplastic, is related to oligoastrocytoma and glioma, and has symptoms including seizures and headache. An important gene associated with Anaplastic Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), and among its related pathways/superpathways are Glioma and DNA Damage. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Anaplastic Oligodendroglioma

About this section

Diseases related to Anaplastic Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 30.9 MGMT IDH2 GFAP
2 glioma 29.5 POT1 IDH2 EGFR CDKN2A
3 glioblastoma 29.5 MGMT IDH2 EGFR CDKN2A
4 brain cancer 29.3 MGMT IDH2 GFAP EGFR
5 glioblastoma multiforme 29.2 MGMT GFAP EGFR CDKN2A
6 brain glioma 29.2 MGMT GFAP EGFR
7 ependymoma 29.2 MGMT GFAP EGFR
8 lynch syndrome 29.0 MGMT EGFR CDKN2A
9 li-fraumeni syndrome 28.9 EGFR CDKN2A
10 grade iii astrocytoma 28.5 MGMT IDH2 GFAP EGFR CDKN2A
11 oligodendroglioma 28.2 POT1 MGMT IDH2 GFAP EGFR CDKN2C
12 glial tumor 10.6
13 anaplastic oligoastrocytoma 10.5
14 astrocytoma 10.5
15 malignant glioma 10.4
16 protoplasmic astrocytoma 10.3 IDH2 GFAP
17 gemistocytic astrocytoma 10.3 IDH2 GFAP
18 glioma susceptibility 1 10.3 IDH2 GFAP
19 arteriovenous malformation 10.2
20 mixed glioma 10.2
21 pleomorphic xanthoastrocytoma 10.2 MGMT GFAP
22 periosteal chondrosarcoma 10.2 IDH2 CDKN2A
23 spinal cord astrocytoma 10.2 MGMT GFAP
24 parkinson disease, late-onset 10.1
25 leukemia, acute lymphoblastic 10.1
26 lymphocytic leukemia 10.1
27 hydrocephalus 10.1
28 neutropenia 10.1
29 central neurocytoma 10.1
30 gangliocytoma 10.1
31 ganglioglioma 10.1
32 congenital hydrocephalus 10.1
33 pilocytic astrocytoma 10.1
34 back pain 10.1
35 rare surgical neurologic disease 10.1
36 breast giant fibroadenoma 10.1 MGMT CDKN2A
37 cornea cancer 10.1 GFAP CDKN2A
38 atypical neurofibroma 10.1 GFAP CDKN2A
39 necrotizing sialometaplasia 10.0 GFAP CDKN2A
40 central nervous system lymphoma 10.0 MGMT CDKN2A
41 juvenile pilocytic astrocytoma 10.0 GFAP CDKN2A
42 cerebral cavernous malformations 10.0
43 endosteal hyperostosis, autosomal dominant 10.0
44 williams-beuren syndrome 10.0
45 lymphoma, hodgkin, classic 10.0
46 myeloma, multiple 10.0
47 lymphoma, non-hodgkin, familial 10.0
48 meningioma, radiation-induced 10.0
49 meningioma, familial 10.0
50 psoriatic arthritis 10.0

Graphical network of the top 20 diseases related to Anaplastic Oligodendroglioma:



Diseases related to Anaplastic Oligodendroglioma
Sources

Symptoms & Phenotypes for Anaplastic Oligodendroglioma

About this section

UMLS symptoms related to Anaplastic Oligodendroglioma:


seizures, headache

GenomeRNAi Phenotypes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.77 EGFR
2 Decreased viability GR00221-A-1 9.77 CDKN2A EGFR POT1 CDKN2C
3 Decreased viability GR00221-A-3 9.77 CDKN2A POT1
4 Decreased viability GR00221-A-4 9.77 CDKN2A EGFR POT1
5 Decreased viability GR00301-A 9.77 CDKN2C
6 Decreased viability GR00342-S-2 9.77 CDKN2C
7 Decreased viability GR00402-S-2 9.77 CDKN2A EGFR POT1 CDKN2C

MGI Mouse Phenotypes related to Anaplastic Oligodendroglioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 CDKN2A CDKN2C EGFR GFAP IDH2
2 neoplasm MP:0002006 9.55 CDKN2A CDKN2C EGFR IDH2 MGMT
3 no phenotypic analysis MP:0003012 9.26 CDKN2A EGFR MGMT POT1
4 respiratory system MP:0005388 8.92 CDKN2A CDKN2C EGFR MGMT
Sources

Drugs & Therapeutics for Anaplastic Oligodendroglioma

About this section

Drugs for Anaplastic Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 297)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
4
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
5
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
6
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
7
Histamine Approved, Investigational Phase 3 51-45-6 774
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
10 Anesthetics Phase 3
11 Analgesics Phase 3
12 Peripheral Nervous System Agents Phase 3
13 Central Nervous System Depressants Phase 3
14 Nootropic Agents Phase 3
15 Cholinesterase Inhibitors Phase 3
16 Cholinergic Agents Phase 3
17 Liver Extracts Phase 3
18 Cola Phase 3
19 Anesthetics, Intravenous Phase 3
20 Narcotics Phase 3
21 Analgesics, Opioid Phase 3
22 Adjuvants, Anesthesia Phase 3
23 Anesthetics, General Phase 3
24 Antineoplastic Agents, Phytogenic Phase 3
25 Tubulin Modulators Phase 3
26 Antimitotic Agents Phase 3
27 Gastrointestinal Agents Phase 3
28 Central Nervous System Stimulants Phase 3
29 Neurotransmitter Agents Phase 3
30 Dexmethylphenidate Hydrochloride Phase 3
31 Neurotransmitter Uptake Inhibitors Phase 3
32 Dopamine Uptake Inhibitors Phase 3
33 Dopamine Agents Phase 3
34 Anti-Allergic Agents Phase 3
35 Serotonin Antagonists Phase 3
36 Histamine H1 Antagonists Phase 3
37 Histamine Antagonists Phase 3
38 Serotonin Agents Phase 3
39
Histamine Phosphate Phase 3 51-74-1 65513
40 Antipruritics Phase 3
41
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
42
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
43
Ethanol Approved Phase 1, Phase 2 64-17-5 702
44
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
45
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
46
Bevacizumab Approved, Investigational Phase 2 216974-75-3
47
Oxcarbazepine Approved Phase 1, Phase 2 28721-07-5 34312
48
Phenobarbital Approved, Investigational Phase 1, Phase 2 50-06-6 4763
49
Phenytoin Approved, Vet_approved Phase 1, Phase 2 57-41-0 1775
50
Carbamazepine Approved, Investigational Phase 1, Phase 2 298-46-4 2554

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
2 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
4 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
6 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
7 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
8 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
9 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
10 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
11 A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas Unknown status NCT00004204 Phase 2 temozolomide
12 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
13 Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma Unknown status NCT00892177 Phase 2 dasatinib
14 Pilot Study to Determine Therapeutic Response of Oral Capecitabine (Xeloda) in Recurrent High Grade Gliomas (HGGs) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria Completed NCT00717197 Phase 2 Capecitabine
15 Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
16 Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal Completed NCT00003465 Phase 2 temozolomide
17 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
18 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma Completed NCT00400816 Phase 2 temozolomide
19 Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
20 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
21 Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2 fenretinide
22 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
23 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
24 A Phase I/II Trial Of MGI114 For Treatment Of Patients With Recurrent Malignant Gliomas Completed NCT00012038 Phase 1, Phase 2 irofulven
25 A Phase I/II Study of Col-3 Administered on a Continuous Daily Oral Schedule in Patients With Recurrent High-Grade Astrocytoma Completed NCT00004147 Phase 1, Phase 2 incyclinide
26 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
27 Bevacizumab in Combination With Irinotecan for Malignant Gliomas Completed NCT00268359 Phase 2 irinotecan hydrochloride
28 A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma Completed NCT00004113 Phase 2 temozolomide
29 A Multi-Center, Open-Label Clinical Study to Evaluate the Safety and Performance of the Proxima GliaSite RTS, a Radiation Delivery System, in Patients With Recurrent Malignant Brain Tumors Undergoing Surgical Resection Completed NCT00003574 Phase 2
30 A Phase II Trial of Poly ICLC in Patients With Recurrent Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
31 ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS Completed NCT00002639 Phase 2 chemotherapy;suramin
32 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
33 Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed NCT00859222 Phase 1, Phase 2 LBH589;bevacizumab
34 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
35 Improved Characterization of Brain Tumors By MRI and MRS Completed NCT00274755 Phase 2 chemotherapy
36 A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
37 A Phase I/II Trial of EMD 121974 for Treatment of Patients With Recurrent Anaplastic Gliomas Completed NCT00006093 Phase 1, Phase 2 cilengitide
38 A Phase II Trial Of Thalidomide And Procarbazine In Adults With Recurrent/Progressive Gliomas Completed NCT00079092 Phase 2 procarbazine hydrochloride;thalidomide
39 A Phase I/II Study of Oral Procarbazine in the Treatment of Recurrent High Grade Astrocytomas Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
40 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
41 A Phase II Trial Of Talampanel In Patients With Recurrent High-Grade Gliomas Completed NCT00064363 Phase 2 talampanel
42 Trial Of Oral Thalidomide, Celecoxib, Etoposide And Cyclophosphamide In Adult Patients With Relapsed Or Progressive Malignant Gliomas Completed NCT00047281 Phase 2 celecoxib;cyclophosphamide;etoposide;thalidomide
43 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
44 A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
45 Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma Completed NCT00619112 Phase 2 temozolomide
46 Phase II Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma Completed NCT00613093 Phase 2 Temodar and O6-Benzylguanine (BG)
47 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
48 Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas Completed NCT00352521 Phase 2 bevacizumab;irinotecan
49 CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor Completed NCT00007982 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa
50 Phase I/II Trial of Pyrazoloacridine and Carboplatin in Patients With Recurrent Glioma Completed NCT00005976 Phase 2 carboplatin;pyrazoloacridine

Search NIH Clinical Center for Anaplastic Oligodendroglioma

Sources

Genetic Tests for Anaplastic Oligodendroglioma

About this section
Sources

Anatomical Context for Anaplastic Oligodendroglioma

About this section

MalaCards organs/tissues related to Anaplastic Oligodendroglioma:

41
Brain, Spinal Cord, Bone, T Cells, Breast, Bone Marrow, Eye
Sources

Publications for Anaplastic Oligodendroglioma

About this section

Articles related to Anaplastic Oligodendroglioma:

(show top 50) (show all 564)
# Title Authors PMID Year
1
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. 9 38
19805356 2009
2
[Temozolomide: Temodal]. 9 38
18347414 2008
3
Serum GFAP is a diagnostic marker for glioblastoma multiforme. 9 38
17998256 2007
4
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. 9 38
17440165 2007
5
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. 9 38
17319279 2007
6
[Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors]. 9 38
17236582 2006
7
Malignant glioma: neuropathology and neurobiology. 9 38
16944363 2006
8
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. 9 38
15455350 2005
9
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. 9 38
11438483 2001
10
Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. 9 38
11307615 2001
11
Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. 9 38
10515227 1999
12
Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. 9 38
10485462 1999
13
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. 9 38
9776413 1998
14
Epidermal growth factor receptor expression in oligodendroglial tumors. 9 38
8686753 1996
15
Lectins: reliable differentiation markers in human oligodendrogliomas. 9 38
8220777 1993
16
Extent of resection and survival for oligodendroglioma: a U.S. population-based study. 38
31407129 2019
17
Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification. 38
31370384 2019
18
A novel PTPRZ1-ETV1 fusion in gliomas. 38
31381204 2019
19
Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control. 38
31141785 2019
20
Incidence trends of adult malignant brain tumors in Finland, 1990-2016. 38
30985227 2019
21
[IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma]. 38
31269600 2019
22
Anaplastic oligodendroglioma metastasizing to the bone marrow: a unique case report and literature review. 38
30526175 2019
23
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. 38
30975663 2019
24
Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report. 38
31248444 2019
25
Anaplastic Oligodendroglioma with Transdural Extension. 38
31254692 2019
26
Scalp metastasis of anaplastic oligodendroglioma: Case report. 38
31125773 2019
27
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. 38
30677248 2019
28
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. 38
31028406 2019
29
Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma. 38
30977078 2019
30
Glioma Tumor Grade Identification Using Artificial Intelligent Techniques. 38
30900029 2019
31
c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas. 38
30878754 2019
32
Anaplastic Oligodendroglioma Found as an Incidental Photopenic Lesion on 18F-FP-CIT PET/CT Image. 38
30672761 2019
33
Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma. 38
30601146 2019
34
Determination of genetic aberrations and novel transcripts involved in the pathogenesis of oligodendroglioma using array comparative genomic hybridization and next generation sequencing. 38
30675227 2019
35
Navigated Transcranial Magnetic Stimulation in Patient with Cranioplasty in Situ: Safe and Accurate Procedure. 38
30296623 2019
36
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics. 38
30738431 2019
37
Glioma Simultaneously Present with Adjacent Meningioma: Case Report and Literature Review. 38
30937052 2019
38
Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma. 38
31386006 2019
39
Prognostic factors associated with survival in patients with anaplastic oligodendroglioma. 38
30699183 2019
40
Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. 38
30446361 2019
41
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT. 38
29912004 2019
42
Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma. 38
30018130 2018
43
Tumour-to-Tumour Metastasis Phenomenon: Metastatic Prostatic Adenocarcinoma within an Anaplastic Oligodendroglioma in the Brain of a Dog. 38
30502799 2018
44
Anaplastic oligodendroglioma with leptomeningeal dissemination in a french bulldog. 38
30185721 2018
45
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. 38
29780148 2018
46
Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics. 38
30361986 2018
47
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. 38
30289152 2018
48
Expression of Oligodendrocyte Precursor Cell Markers in Canine Oligodendrogliomas. 38
29852819 2018
49
Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. 38
30193580 2018
50
Fluorescence-guidance in non-Gadolinium enhancing, but FET-PET positive gliomas. 38
30032095 2018
Sources

Variations for Anaplastic Oligodendroglioma

About this section

ClinVar genetic disease variations for Anaplastic Oligodendroglioma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CIC NM_015125.4(CIC): c.643C> T (p.Arg215Trp) single nucleotide variant Likely pathogenic 19:42791757-42791757 19:42287605-42287605
Sources

Expression for Anaplastic Oligodendroglioma

About this section
Search GEO for disease gene expression data for Anaplastic Oligodendroglioma.
Sources

Pathways for Anaplastic Oligodendroglioma

About this section

Pathways related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Glioma 37
Show member pathways
 12.18 EGFR CDKN2C CDKN2A
2
DNA Damage 4
11.8 MGMT CDKN2C CDKN2A
3
Bladder cancer 37 1
11.23 EGFR CDKN2A
4
Regulation of Telomerase 1
11.14 POT1 EGFR
5
Photodynamic therapy-induced AP-1 survival signaling. 1
10.96 EGFR CDKN2A
6
Glioblastoma Multiforme 64
10.84 MGMT EGFR CDKN2A
7
Oncogene Induced Senescence 66
10.46 CDKN2C CDKN2A
Sources

GO Terms for Anaplastic Oligodendroglioma

About this section

Biological processes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA repair GO:0045739 9.16 MGMT EGFR
2 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 8.96 CDKN2C CDKN2A
3 negative regulation of phosphorylation GO:0042326 8.62 CDKN2C CDKN2A

Molecular functions related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.13 EGFR CDKN2C CDKN2A
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN2C CDKN2A
Sources

Sources for Anaplastic Oligodendroglioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....